respiratorisch

Seit der Aufnahme war der Patient im Wesentlichen oligo symptomatisch sowie kardio respiratorisch stabil.

Since the establishment of the patient was essentially oligo symptomatic and cardio respiratory stable.

Das erfindungsgemäße Verfahren eignet sich besonders zur inhalativen Applikation der nachfolgenden Wirkstoffe, ist aber nicht darauf beschränkt: Insulin, Calcitonin, Erythropoietin (EPO), Faktor VIII, Faktor IX, Cyclosporin, Granulozyte Colony Stimulating Factor (GCSF), Alpha-1 Proteinase Inhibitor, Elcatonin, Granulocyte Makrophage Colony Stimulating Factor (GMCSF), Wachstumshormone, menschliches Wachstumshormon (HGH), Growth hormone releasing hormone (GHRH), Heparin, niedermolekulares Heparin (LMWH), Interferon alpha, Interferon beta, Interferon gamma, Interleukin-2, Luteinizing hormone releasing hormone (LHRH), Somatostatin, Somatostatin-Analoge einschließlich Octreotide, Vasopressinanaloge , Follikel stimulierendes Hormon (FSH), Insulin like growth factor, Insulintropin, Interleukin-1 Rezeptorantagonist, Interleukin-3, Interleukin-4, Interleukin-6, Macrophage colony stimulating Factor (M-CSF), Nerven-Wachstumsfaktor, Parathyroidhormon (PTH), Thymosin alpha 1, IIb/-IIIa Inhibitor, Alpha-1 Antitrypsin, Antikörper gegen respiratorisch syncytischen Virus, Cystic fibrosis transmembrane regulator gene (CFTR), Desoxyribonuclease (Dnase), Bactericide, permeability increasing protein (BPI), anti-CMV Antikörper, Interleukin-1 Rezeptor, Retinol-Säuren, Pentamidine, Albuterolsulfat, Metaproterenolsulfat, Beclomethasondiprepionat, Triamcinolonacetamid, Budesonidacetonide, Ipratropiumbromid, Flunisolide, Fluticasone, Cromolynsodium, Ergotamintartrat und die Analogen, Agonisten und Antagonisten der oben genannten Stoffe.

The method according to the present invention is particularly suited for inhalative application of the following active agents, but is not limited thereto: Insulin, calcitonin, erythropoietin (EPO), factor VIII, factor IX, cyclosporin, granulocyte colony stimulating factor (GCSF), alpha-1-proteinase inhibitor, elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth hormones, human growth hormone (HGH), growth hormone releasing hormone (GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin-2, luteinizing hormone releasing hormon (LHRH), somatostatin, somatostatin analogues including octreotides, vasopressin analogues, follicle stimulating hormone (FSH), insuline-like growth factor, insulintropin, interleukin-I-receptor antagonist, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor (M-CSF), nerve growth factor, parathyroid hormone (PTH), thymosin alpha 1, IIb/IIIa-inhibitor, alpha-1-antitrypsin, antibodies against respiratory syncytial virus, cystic fibrosis transmembrane regulator gene (CFTR), deoxyribonuclease (DNAse), bactericides, permeability increasing protein (BPI), anti-CMV antibodies, interleukin-I receptor, retinoic acids, pentamidine, albuterol sulfate, metaproterenol sulfate, beclomethasondiprepionate, triamcinolon acetamide, budesonid acetonide, ipratropium bromide, flunisolide, fluticasone, chromolyn sodium, ergotamin tartrate, and the analogues, agonists and antagonists of the aforementioned substances.

Die Erfindung ist besonders geeignet zur inhalativen Applikation von verschiedenen Wirkstoffen (ist aber nicht darauf beschränkt) wie: Insulin, Calcitonin, Erythropoietin (EPO), Faktor VIII, Faktor IX, Cyclosporin, Granulozyte Colony Stimulating Factor (GCSF), Alpha-1 Proteinase Inhibitor, Elcatonin, Granulocyte Makrophage Colony Stimulating Factor (GMCSF), Wachstumshormone, menschliches Wachstumshormon (HGH), Growth hormon releasing hormone (GHRH), Heparin, niedermolekulares Heparin (LMWH), Interferon alpha, Interferon beta, Interferon gamma, Interleukin-2, Luteinizing hormone releasing hormone (LHRH), Somatostatin, Somatostatin-Anlaloge einsschließlich Octreotide, Vasopressinanaloge, Follikel stimulierendes Hormon (FSH), Insulin like growth factor, Insulintropin, Interleukin-1 Rezeptorantagonist, Interleukin-3, Interleukin-4, Interleukin-6, Macrophage colony stimulating Factor (M-CSF), Nerven-Wachstumsfaktor, Parathyroidhormon (PTH), Thymosin alpha 1, IIb/IIIa Inhibitor, Alpha-1 Antitrypsin, Antikörper gegen respiratorisch syncytischen Virus, Cystic fibrosis transmembrane regulator gene (CFTR), Desoxyribonuclease (Dnase), Bactericide, permeability increasing protein (BPI), anti-CMV Anikörper, Interleukin-1 Rezeptor, Retinol, Retinyl-Ester, Tocopherole und deren Ester, Tocotrienole und deren Ester, Carotinoide insbesondere Beta-Carotin und andere natürliche und synthetische Antioxidantien, Retinol-Säuren, Pentamidine, Albuterolsulfat, Metaproterenolsulfat, Beclomethasondiprepionat, Triamcinolonacetamid, Budesonidacetonide, Ipratropiumbromid, Flunisolide, Fluticasone, Cromolynsodium, Ergotamintartrat und die Analogen, Agonisten und Antagonisten der oben genannten Stoffe.

The present invention is particularly suited for (but not restricted to) the application of different active ingredients by inhalation, such as: Insulin, calcitonin, erythropoietin (EPO), Factor VIII, Factor IX, cyclosporin, granulocyte colony stimulating factor (GCSF), alpah-1 proteinase inhibitor, elcatonin, granulocyte makrophage colony stimulating factor (GMCSF), growth hormones, human growth hormones (HGH), growth hormone releasing hormones (GHRH), heparin, low-molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin-2, luteinizing hormone releasing hormone (LHRH), somatostatin, somatostatin analogues including octreotide, vasopressin analogues, follicle stimulating hormone (FSH), insulin-like growth factor, insulinotropin, interleukin-1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor (MCSF), nerve growth factor, parathyroid hormone (PTH), thymosin alpha 1, IIb/IIIa inhibitor, alpha-1 antitrypsin, antibodies against respiratory syncytical viruses, cystic fibrosis transmembrane regulator gene (CFTR), desoxyribonuclease (DNase), bactericides, permeability-increasing protein (BPI), anti-CMV antibodies, interleukin-1 receptor, retinol, retinyl ester, tocopheroles and their esters, tocotrienols and their esters, carotinoides, in particular beta carotene and other natural and synthetic anti-oxidants, retinol acids, pentamidines, albuterol sulfate, metaproterenol sulfate, beclomethasone diprepionate, triamcinolone acetamide, budesonide acetonide, ipratropium bromide flunisolides, fluticasones, cromolyn sodium, ergotamine tartrate and their analogues, agonists and antagonists of the aforementioned substances.

Die Erfindung ist besonders geeignet zur inhalativen Applikation von verschiedenen Wirkstoffen (ist aber nicht darauf beschränkt) wie: Insulin, Calcitonin, Erythropoietin (EPO), Faktor VIII, Faktor IX, Cyclosporin, Granulozyte Colony Stimulating Factor (GCSF), Alpha-1 Proteinase Inhibitor, Elcatonin, Granulocyte Makrophage Colony Stimulating Factor (GMCSF), Wachstumshormone, menschliches Wachstumshormon (HGH), Growth hormon releasing hormone (GHRH), Heparin, niedermolekulares Heparin (LMWH), Interferon alpha, Interferon beta, Interferon gamma, Interleukin-2, Luteinizing hormone releasing hormone (LHRH), Somatostatin, Somatostatin-Anlaloge einsschließlich Octreotide, Vasopressinanaloge, Follikel stimulierendes Hormon (FSH), Insulin like growth factor, Insulintropin, Interleukin-I Rezeptorantagonist, Interleukin-3, Interleukin-4, Interleukin-6, Macrophage colony stimulating Factor (M-CSF), Nerven-Wachstumsfaktor, Parathyroidhormon (PTH), Thymosin alpha 1, IIb/IIIa Inhibitor, Alpha-1 Antitrypsin, Antikörper gegen respiratorisch syncytischen Virus, Cystic fibrosis transmembrane regulator gene (CFTR), Desoxyribonuclease (Dnase), Bactericide, permeability increasing protein (BPI), anti-CMV Anikörper, Interleukin-1 Rezeptor, Retinol, Retinyl-Ester, Tocopherole und deren Ester, Tocotrienole und deren Ester, Carotinoide insbesondere Beta-Carotin und andere natürliche und synthetische Antioxidantien, Retinol-Säuren, Pentamidine, Albuterolsulfat, Metaproterenolsulfat, Beclomethasondiprepionat, Triamcinolonacetamid, Budesonidacetonide, Ipratropiumbromid, Flunisolide, Fluticasone, Cromolynsodium, Ergotamintartrat und die Analogen, Agonisten und Antagonisten der oben genannten Stoffe.

[0024] The invention is particularly suited for inhalation application of different active ingredients, such as the following ones (without being restricted thereto): Insulin, calcitonin, erythropoietin (EPO), factor VII, factor IX, cylcosporin, granulozyte colony stimulating factor (GCSF), alpha-1-proteinase inhibitor, elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth hormones, human growth hormone (HGH), growth hormone releasing hormone (GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin-2, luteinizing hormone releasing hormone (LHRH), somatostatin, somatostatin-analogs, including octreotides, vasopressin analogs, follicle stimulating hormone (FSH), insulin-like growth factor, insulintropin, interleukin-I receptor antagonist, interleukin-3, interleukin-4, interleukin-6, macrophage colony stimulating factor (M-CSF), nerve growth factor, parathryoid hormone (PTH), thymosin alpha 1, IIb/IIIa inhibitor, alpha-1 antitrypsin, antibodies against respiratorily syncytic virus, cystic fibrosis transmembrane regulator gene (CFTR), desoxyribonuclease (Dnase), bactericides, permeability increasing protein (BPI), anti-CMV antibodies, interleukin-1-receptor, retinol, retinyl-ester, tocopherols and their esters, tocotrienols and their esters, carotinoids, in particular beta carotin and other natural and synthetic antioxidants, retinol acids, pentamides, albuterolsulfate, metaproterenolsulfate, beclomethasonedipropionate, triamcinolonacetamide, budesonidacetonides, ipratropium bromide, flunisolides, fluticasones, cromolyn potassium, ergotamine tartrate and the analogs, agonists and antagonists of the above-mentioned substances.